ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
0
views
0
references
Top references
cited by
7
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
669
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Empagliflozin increases cardiac energy production in diabetes novel translational insights into the heart failure benefits of SGLT2 inhibitors
Author(s):
Verma S.
,
S. VERMA
,
S. RAWAT
,
KL HO
,
K.L. HO
,
S Rawat
,
S Verma
,
K.L. Ho
Publication date:
2018
Journal:
JACC Basic Trans Sci
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Preventive and Emergency Medicine Insights
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
669
Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment
Authors:
Carina Kirstine Klarskov
,
Helga Holm Schultz
,
Frederik Persson
…
SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β 1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial
Authors:
Yuan Tian
,
Xiao-min Chen
,
Xian-ming Liang
…
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Authors:
See all similar
Cited by
6
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Authors:
Gary D. Lopaschuk
,
Subodh Verma
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Authors:
Qutuba Karwi
,
Kim Ho
,
Simran Pherwani
…
Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System? ∗
Authors:
Subodh Verma
See all cited by